Connect with us

Cultured

Regen BioPharma Inc (OTCMKTS: RGBP) Under Accumulation as Biotech Sleeper Makes Major Reversal Northbound (A look at Intellectual Property / mRNA Vaccine)

Regen BioPharma Inc (OTCMKTS: RGBP) is on the rise in recent trading since reversing off $0.0034 lows last week. RGBP has seen significant decline in recent…

Published

on

Regen BioPharma Inc (OTCMKTS: RGBP) is on the rise in recent trading since reversing off $0.0034 lows last week. RGBP has seen significant decline in recent months with a lack of news from the Company and an aggressive noteholder that has decimated the share price since it was trading over $0.08 in fall 2021. Now RGBP looks like its oversold and ready for a major reversal and speculators are beginning to accumulate into the selling which is starting to wane as the noteholder is running out of shares. Regen has been busy since the last time we reported on it when they were just coming off a number of wins including going “pink current” and becoming fully compliant, settlings the lawsuit with Chemdiv, growing its patent portfolio as well as granting two licensees to Oncology Pharma for which Regen was paid $1.9 million in cash & securities. Regen has begun a development program to commercialize its modified mRNA anti-cancer vaccine targeting the Survivin protein. They also announced a program to accelerate the clinical development of its NR2F6 therapies. Regen plans to combine modified mRNA technology with its existing siRNA intellectual property targeting the NR2F6 nuclear receptor which has been identified as a potentially very important immune cell inhibitor and cancer stem cell differentiator.  

Microcapdaily has been reporting on RGBP for years stating in an earlier article: “RGBP is one of the most followed stocks in small caps with a huge investors base and it has a long history of big moves skyrocketing to 8 cents plus twice over the past 12 months. There are also plenty of buyout rumors on RGBP; according to many investors It appears there may be a possible merger acquisition looming with Precigen or another big pharma which would make sense as the CEO of Precigen (PGEN) Helen Sabzevari is on RGBP’s Scientific Advisory Board. PGEN trades on Nasdaq with a Market Cap of $766 million. RGBP is in the same clinical therapeutic niche market of Oncology-Immunology candidate drug development that Precigen is in including the same mRNA vaccine technology so logically speaking it would make sense if PGEN straight up buys-out RGBP or does a merger acquisition and the motive to do this are the numerous valuable Patents RGBP owns that address enormous billion-dollar markets.”  

Sign Up now for our 100% FREE Penny Stock Newsletter

Regen BioPharma Inc (OTCMKTS: RGBP) is a biotechnology company focused on the immunology and immunotherapy space. Currently, Regen is advancing small molecule therapies for treating cancer and autoimmune disorders by modulating the Checkpoint NR2F6.  The company is also developing products treating blood disorders using small molecules and gene silencing (DiffronC), treating cancer with cellular immunotherapy (dCellVax), modulating key molecular processes in cancer stem cell through its patented molecular targeting approaches (BORIS), and repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients (HemaXellerate). RGBP owns a very valuable patent porfolio.

Big things happening here:

1). on 4/8/21 he files an 8K which in and of itself is a dead give-a-away of what he’s up to. The question begs why would he file an 8K that specifically gives himself exclusive control of voting rights in negotiations for the sale of the company during the bidding process that’s specifically intended to prevent a Hostile Take Over? And in doing this he states quote: “persons of interest who want to ACQUIRE RGBP must negotiate directly.” This is in reference to himself having sole control of voting rights that this 8K gives him. Other words, negotiations for sale of the company can’t go around him to his board which is a typical move in any hostile take over. This by itself reveals what he’s up to in addition to MANY other factors shown below. https://sec.report/Document/0001607062-21-000145/ 

2). he recently hired a Firm to get OTC current with FULL disclosure reporting. This has to do not only with SEC compliance to remain listed on the OTC beyond September 2021 but ALSO it provides transparency for any potential Big Pharma buyers that would never consider buying a company otherwise. 

3). on 6/1/21 he files another 8K that has to do with resolving a lawsuit. This would be important to any potential buyers for reason a pending unresolved lawsuit would likely complicate negotiations of a buy out, or it would be a deterrent altogether. https://sec.report/Document/0001607062-21-000145/ 

4). we see him moving to get all his expired Patents updated. Logically this move would be consistent with preparing for an acquiring company to take over the patents then turn around and file an FDA IND post buy out in order to immediately place those candidate drug Patents in their clinical trials pipeline. 

5). lastly he’s not updating the company website that’s been outdated for years. Why would he invested time, energy, and money in updating his company website if he’s about to sell the company? 

On April 7, 2021 KCL Therapeutics, Inc. (“KCL”) (RGBP subsidiary) entered into an agreement with Oncology Pharma, Inc. whereby KCL granted to Licensee an exclusive right and license for the development and commercialization of certain intellectual property for the treatment in humans of colon cancer for a term of fifteen years from April 7, 2021. 

As consideration to KCL for the rights and license granted pursuant to the Agreement Licensee shall: pay to KCL a nonrefundable fee of Fifty Thousand common shares of Oncology Pharma, Inc. no later than April 20,2021, pay to KCL royalties equal to five percent (5%) of the Net Sales as Net Sales are defined in the Agreement of any Licensed Products in a quarter. pay to KCL ten percent (10%) of all consideration (in the case of in-kind consideration, at fair market value as monetary consideration) received by Licensee from sublicensees, excluding royalties from sublicensees based on Net Sales of any Licensed Products for which KCL receives payment. ONCP is trading at $33 at an $847 million market valuation, the 50,000 shares are worth $1,500,000) 

To Find out the inside Scoop on RGBP Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

RGBP

Earlier this year RGBP announced a program to accelerate the clinical development of its NR2F6 therapies. The Company intends to combine modified mRNA technology with Regen’s existing siRNA (small interfering RNA) intellectual property targeting the NR2F6 nuclear receptor which has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. mRNA is a single-stranded molecule that carries genetic code from DNA in a cell’s nucleus to ribosomes (the cell’s protein-making machinery).    

Regen has filed an Investigational New Drug Application (IND#16928) for their drug termed tCellVax   with the U.S. FDA. tCellVax is intended to utilize siRNA to silence NR2F6 activity in human immune cells thereby activating these immune cells in such a way that they can attack cancer cells. The Company believes that adding new intellectual property utilizing modified mRNA will profoundly simplify the drug development process and thus speed development. Dyo Biotechnologies has been contracted to assist Regen with the development of the above-mentioned technology. 

On March 16 RGBP responded to numerous requests for updates on its intellectual property (IP) Portfolio. The Company has an extensive intellectual property portfolio consisting of granted patents, published applications and pending applications. Regen’s intellectual property portfolio includes 8 issued patents and 13 published patent applications. Zander Therapeutics, Inc. (a company under common control) has been granted an exclusive license to develop and commercialize IP controlled by the Company for non-human veterinary therapeutic use. Regen has granted an exclusive license to Oncology Pharma, Inc. to develop and commercialize “Antigen specific mRNA cellular cancer vaccines” for the treatment of pancreatic cancer and KCL Therapeutics, Inc. has granted an exclusive license to Oncology Pharma, Inc. to develop and commercialize certain intellectual property for the treatment of colon cancer. RGBP CEO David Koos said at the time: “I believe our tCellVax drug as it stands today is a potentially major new development in the field of cancer immunotherapy. We believe that by adding our new mRNA intellectual property to tCellVax we can simplify its administration to patients and thus create a much more marketable drug,” says David Koos, CEO and Chairman of Regen. “An RNA-based checkpoint inhibitor will be a first-in-class drug.”  

RGBP is led by CEO David Koos who has over 30 years of investment banking and venture capital experience.  He has a deep knowledge of startup businesses, public markers and SEC reporting companies.  Dr. Koos has extensive relationships with large and small financial institutions, hedge funds and entities that Regen BioPharma expects to leverage for company growth. Dr. Koos has a Ph.D. in Sociology and a Doctor of Business Administration with an emphasis in finance.  Additionally, he has authored / coauthored  numerous peer reviewed journal articles. Dr. Koos has been working hard behind the scenes getting all the filings into OTC Markets Group in order to go “pink current” 

 

For more on RGBP Subscribe Right Now!

RGBP is on the rise in recent trading since reversing off $0.0034 lows last week. RGBP has seen significant decline in recent months with a lack of news from the Company and an aggressive noteholder that has decimated the share price since it was trading over $0.08 in fall 2021. Now RGBP looks like its oversold and ready for a major reversal and speculators are beginning to accumulate into the selling which is starting to wane as the noteholder is running out of shares. Regen has been busy since the last time we reported on it when they were just coming off a number of wins including going “pink current” and becoming fully compliant, settlings the lawsuit with Chemdiv, growing its patent portfolio as well as granting two licensees to Oncology Pharma for which Regen was paid $1.9 million in cash & securities. Regen has begun a development program to commercialize its modified mRNA anti-cancer vaccine targeting the Survivin protein. They also announced a program to accelerate the clinical development of its NR2F6 therapies. Regen plans to combine modified mRNA technology with its existing siRNA intellectual property targeting the NR2F6 nuclear receptor which has been identified as a potentially very important immune cell inhibitor and cancer stem cell differentiator. RGBP buyout rumors abound; according to many investors It appears there may be a Potential Merger Acquisition looming with Precigen OR another Big Pharma and if so it would make perfect sense for the following reasons. The CEO of Precigen (PGEN) Helen Sabzevari is on RGBP’s Scientific Advisory Board. PGEN trades on Nasdaq with a Market Cap of $1.3B and has an extensive clinical trials pipeline in Immunology-Oncology that includes development of mRNA vaccines therapies. https://precigen.com/about. Regenis in the same clinical therapeutic niche market of Oncology-Immunology candidate drug development that RGBP is in. 100% identical including the same mRNA vaccine technology so logically speaking it would make sense if PGEN straight up buys-out RGBP OR does a Merger Acquisition and the motive to do this are the numerous valuable Patents RGBP owns that have Billion Dollar Market Capacity. Koos is presently on an aggressive campaign to pull everything together about RGBP in the shortest amount of time to apparently ready the company for SALE! We will be updating on RGBP when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with RGBP.

Sign Up now for our 100% FREE Penny Stock Newsletter

Disclosure: we hold no position in RGBP either long or short and we have not been compensated for this article

The post Regen BioPharma Inc (OTCMKTS: RGBP) Under Accumulation as Biotech Sleeper Makes Major Reversal Northbound (A look at Intellectual Property / mRNA Vaccine) first appeared on Micro Cap Daily.

Read More